Teva's migraine therapy meets Phase II endpoints

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said TEV-48125 ( LBR-101) met the primary endpoint of reducing headaches vs. placebo in a Phase IIb trial to treat chronic migraine.

The 261-patient study tested two doses of the humanized mAb that blocks the calcitonin gene-related peptide ( CGRP) from binding to its receptor. Teva said both doses met the primary endpoint of reducing the cumulative number of headache hours per month from baseline to 12 weeks. Both doses also reduced the days per month that patients experienced headaches of at least moderate severity, a secondary endpoint. Teva reported no treatment-related serious adverse events. ...